MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC

MAIA Biotechnology, Inc.

Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.
FDA granted Fast Track designation for ateganosine, a dual mechanism telomere-targeting agent, for third-line NSCLC treatment.
Statistical assessments based on Phase 2 data point to high probability of technical success in Phase 3 full approval trial.
Interim Phase 3 data expected next year; may support FDA discussion for early full commercial approval in third-line NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.